IDEXX Laboratories Stock News

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Monday, November 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference cal...

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. “Karen i...

The Nasdaq-100 traded almost exactly sideways in August 2025, posting a 0.9% gain. But it wasn't a slow period for everybody.

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Jay Mazelsky - President, CEO & Director Andrew Emerson - Executive VP, CFO & Treasurer Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Good afternoon, everyone. My na...

If you buy a stock that goes up 20% in a year, I'd say you made a good investment. After all, the S&P 500 (^GSPC 0.51%) returns somewhere around 10% annually on average.

The Nasdaq Composite (^IXIC -0.82%) is one of the U.S. stock market's three major indexes, along with the S&P 500 and Dow Jones. It contains virtually every stock listed on the Nasdaq stock exchange and has been the best-performing index of the three over the past decade by a significant margin.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 202...

Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses, guidance cuts, and Medicare Advantage mispricing, despite its long-term potential to restore profitability. Thermo Fisher and argenx detracted from performance amid macro headwinds and lower-than...